HomeCompareDFGR vs MRK

DFGR vs MRK: Dividend Comparison 2026

DFGR yields 4.21% · MRK yields 2.81%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRK wins by $31.4K in total portfolio value
10 years
DFGR
DFGR
● Live price
4.21%
Share price
$26.58
Annual div
$1.12
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.3K
Annual income
$551.87
Full DFGR calculator →
MRK
Merck & Co. Inc.
● Live price
2.81%
Share price
$118.10
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$57.7K
Annual income
$10,113.78
Full MRK calculator →

Portfolio growth — DFGR vs MRK

📍 MRK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDFGRMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DFGR + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DFGR pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DFGR
Annual income on $10K today (after 15% tax)
$358.02/yr
After 10yr DRIP, annual income (after tax)
$469.09/yr
MRK
Annual income on $10K today (after 15% tax)
$238.95/yr
After 10yr DRIP, annual income (after tax)
$8,596.71/yr
At 15% tax rate, MRK beats the other by $8,127.62/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DFGR + MRK for your $10,000?

DFGR: 50%MRK: 50%
100% MRK50/50100% DFGR
Portfolio after 10yr
$42.0K
Annual income
$5,332.82/yr
Blended yield
12.69%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

DFGR
No analyst data
MRK
Analyst Ratings
24
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+8.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DFGR buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDFGRMRK
Forward yield4.21%2.81%
Annual dividend / share$1.12$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$26.3K$57.7K
Annual income after 10y$551.87$10,113.78
Total dividends collected$4.9K$29.8K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: DFGR vs MRK ($10,000, DRIP)

YearDFGR PortfolioDFGR Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$11,121$421.20$11,213$373.04$92.00MRK
2$12,337$437.78$12,667$512.06$330.00MRK
3$13,655$453.89$14,439$708.14$784.00MRK
4$15,080$469.49$16,640$988.16$1.6KMRK
5$16,621$484.58$19,432$1,394.07$2.8KMRK
6$18,283$499.13$23,057$1,992.90$4.8KMRK
7$20,076$513.14$27,889$2,894.79$7.8KMRK
8$22,008$526.60$34,518$4,286.29$12.5KMRK
9$24,088$539.51$43,912$6,494.35$19.8KMRK
10$26,326$551.87$57,714$10,113.78$31.4KMRK

DFGR vs MRK: Complete Analysis 2026

DFGRStock

DFGR is designed to provide exposure to the global broad real estate industry with a particular focus on REITs. The fund actively invests in companies of any size that generate at least 50% of their revenue or have at least 50% of their assets invested in residential, commercial, industrial, or other real estate industries. REITs or REIT-like entities are also eligible for inclusion. Selection is done through an integrated investment approach, with certain securities adjusted or excluded based on several factors, including free float, stock momentum, liquidity, size, relative price, profitability, and costs as per the discretion of the advisor. Final constituents are market cap-weighted, with country or region weights implemented, where applicable. Following the funds global exposure, it aims to purchase securities only from approved markets, as identified by the advisor, and in at least three different countries, including the US. Derivatives may be used to leverage exposure or manage cash. Lending of portfolio securities is permitted to generate additional income.

Full DFGR Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this DFGR vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DFGR vs SCHDDFGR vs JEPIDFGR vs ODFGR vs KODFGR vs MAINDFGR vs JNJDFGR vs ABBVDFGR vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.